LncRNA Information | ||||||
---|---|---|---|---|---|---|
ID | EL0934 | Name | MRAK052686 | Aliases | N/A | |
Species | Homo sapiens | Chromosome | N/A | Start site | N/A | |
End site | N/A | Chain | N/A | Exon NO. | N/A | |
Assembly | N/A | Class | N/A | NCBI accession | N/A | |
Ensembl | N/A | Sequence | N/A |
Disease | |||||||||
---|---|---|---|---|---|---|---|---|---|
Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
Nonalcoholic fatty liver disease | N/A | N/A | N/A | N/A | Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. MRAK052686, was found strongly correlated with the antioxidant factor Nrf2, and both genes were down-regulated by the steatotic liver. The reduced expression of MRAK052686 and Nrf2 was completely reversed by BBR treatment, suggesting a new mechanism accounting for the therapeutic effect of BBR. | 25623289 | LncRNADisease | ||